Anacor Pharmaceuticals

Anacor Pharmaceuticals company information, Employees & Contact Information

Updated June 2026

Quick answer

Anacor Pharmaceuticals is a Pharmaceutical Manufacturing company and founded in 2002. It has approximately 33 employees on record. Contact data was last refreshed in June 2026. Find Anacor Pharmaceuticals's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Anacor was a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered and is developing five clinical compounds, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK '052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis.

Company Details

Employees
33
Founded
2002
Address
1020 East Meadow Circle, Palo Alto,ca 94303-4230,united States
Phone
(650) 543-7500
Email
in****@****cor.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
anacor.com
HQ
Palo Alto, CA
Looking for a particular Anacor Pharmaceuticals employee's phone or email?

Anacor Pharmaceuticals Questions

News

Pfizer Completes Anacor Acquisition - CHEManager

Pfizer Completes Anacor Acquisition CHEManager

(PDF) Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis - researchgate.net

(PDF) Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis researchgate.net

Tavaborole Approved by DFA For Treatment Of Onychomycosis of the Toenails - Fierce Biotech

Tavaborole Approved by DFA For Treatment Of Onychomycosis of the Toenails Fierce Biotech

Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel - Reuters

Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel Reuters

Pfizer completes acquisition of Anacor Pharmaceuticals - European Pharmaceutical Review

Pfizer completes acquisition of Anacor Pharmaceuticals European Pharmaceutical Review

Pfizer to Acquire Anacor Pharmaceuticals for $5.2 Billion (Published 2016) - The New York Times

Pfizer to Acquire Anacor Pharmaceuticals for $5.2 Billion (Published 2016) The New York Times

Pfizer wins quick reward from buyout of Anacor with approval of eczema drug expected to be blockbuster - Fierce Pharma

Pfizer wins quick reward from buyout of Anacor with approval of eczema drug expected to be blockbuster Fierce Pharma

Pfizer to buy Anacor for eczema ointment - Chemistry World

Pfizer to buy Anacor for eczema ointment Chemistry World

Pfizer to acquire Anacor - Chemical & Engineering News

Pfizer to acquire Anacor Chemical & Engineering News

First-in-Class Antifungal Available for Toenail Onychomycosis - Medical Professionals Reference

First-in-Class Antifungal Available for Toenail Onychomycosis Medical Professionals Reference

Pfizer to buy Anacor in $5.2bn deal for access to eczema gel - The Guardian

Pfizer to buy Anacor in $5.2bn deal for access to eczema gel The Guardian

Pfizer's Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move -- Here's Why - Fox Business

Pfizer's Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move -- Here's Why Fox Business

Anacor Pharmaceuticals and MMV sign agreement to pursue promising compound for malaria - Medicines for Malaria Venture

Anacor Pharmaceuticals and MMV sign agreement to pursue promising compound for malaria Medicines for Malaria Venture

Pfizer To Buy Anacor Pharmaceuticals For $5.2B - International Business Times

Pfizer To Buy Anacor Pharmaceuticals For $5.2B International Business Times

AN2 upsizes IPO, teeing up bid to revitalize antibiotic let go by GSK and Pfizer - Fierce Biotech

AN2 upsizes IPO, teeing up bid to revitalize antibiotic let go by GSK and Pfizer Fierce Biotech

Pfizer to buy toenail fungus treatment maker Anacor for $5bn - The Telegraph

Pfizer to buy toenail fungus treatment maker Anacor for $5bn The Telegraph

Pfizer's Anacor deal showcases new wave of eczema therapies - The Himalayan Times

Pfizer's Anacor deal showcases new wave of eczema therapies The Himalayan Times

Top Anacor Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant